Table 2 Risk profile changes.
From: Oropharyngeal cancer outcomes correlate with p16 status, multinucleation and immune infiltration
Fraction of patients | ||||
|---|---|---|---|---|
Pack-years | 2000–2005 | 2006–2010 | 2011–2015 | |
Tobacco exposure | <10 | 0.2 | 0.16 | 0.28 |
≥10 | 0.8 | 0.84 | 0.72 | |
<30 | 0.36 | 0.28 | 0.49 | |
≥30 | 0.64 | 0.72 | 0.51 | |
Mean | 44.39 | 45.46 | 32.16 | |
Median | 40 | 41.5 | 30 | |
p16—clinical | Neg | 0.68 | 0.48 | 0.36 |
Pos | 0.32 | 0.52 | 0.64 | |
p16—research | 0–25 | 0.58 | 0.41 | 0.33 |
(% tumor cells with strong nuclear staining) | 25–50 | 0.03 | 0.02 | 0.08 |
50–75 | 0.12 | 0.03 | 0.06 | |
75–100 | 0.27 | 0.54 | 0.53 | |
